[go: up one dir, main page]

PE20160113A1 - Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2 - Google Patents

Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2

Info

Publication number
PE20160113A1
PE20160113A1 PE2015002561A PE2015002561A PE20160113A1 PE 20160113 A1 PE20160113 A1 PE 20160113A1 PE 2015002561 A PE2015002561 A PE 2015002561A PE 2015002561 A PE2015002561 A PE 2015002561A PE 20160113 A1 PE20160113 A1 PE 20160113A1
Authority
PE
Peru
Prior art keywords
manufacturing processes
crystal forms
mdm2 inhibitor
chlorophenyl
intermediates
Prior art date
Application number
PE2015002561A
Other languages
English (en)
Inventor
Matthew Bio
Sebastien Caille
Brian Cochran
Yuanqing Fang
Sarah Wortman
Brian S Lucas
Lawrence R Mcgee
Filisaty Vounatsos
Sean Wiedemann
Brian M Fox
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160113(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20160113A1 publication Critical patent/PE20160113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion proporciona procesos para fabricar acido 2-((3R, 5R, 6S)-5-(3-clorofenil)-6-(4-clorofenil)-1-((S)-1-(isipropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il) acetico de formula (I), asi como intermediarios y procesos para fabricar los intermediarios. Tambien se proporcionan formas cristalinas del compuesto y los intermediarios. Conocido tambien como: {(3R, 5R, 6S)-5-(3-clorofenil)-6-(4-clorofenil)-1-[(2S)-1-(isopropilsulfonil)-3-metil-2-butani]-3-metil-2-oxo-3-piperidinil} acetico acido
PE2015002561A 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2 PE20160113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10

Publications (1)

Publication Number Publication Date
PE20160113A1 true PE20160113A1 (es) 2016-03-03

Family

ID=51063849

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020000392A PE20210153A1 (es) 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2
PE2015002561A PE20160113A1 (es) 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2020000392A PE20210153A1 (es) 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2

Country Status (38)

Country Link
US (10) US9376386B2 (es)
EP (2) EP3805232A1 (es)
JP (5) JP6998655B2 (es)
KR (4) KR20230019216A (es)
CN (3) CN105358530A (es)
AP (1) AP2015008891A0 (es)
AR (3) AR096582A1 (es)
AU (5) AU2014278428B2 (es)
BR (2) BR112015031004B1 (es)
CA (4) CA2914723C (es)
CL (3) CL2015003589A1 (es)
CR (2) CR20210290A (es)
CY (1) CY1123661T1 (es)
DK (1) DK3008039T3 (es)
EA (3) EA201891642A1 (es)
ES (1) ES2851023T3 (es)
HR (1) HRP20202065T1 (es)
HU (1) HUE053047T2 (es)
IL (4) IL297860A (es)
JO (2) JOP20200296A1 (es)
LT (1) LT3008039T (es)
MA (3) MA53572A1 (es)
MX (2) MX379872B (es)
MY (2) MY205257A (es)
NZ (1) NZ714821A (es)
PE (2) PE20210153A1 (es)
PH (2) PH12020550916A1 (es)
PL (1) PL3008039T3 (es)
PT (1) PT3008039T (es)
RS (1) RS61192B1 (es)
SG (2) SG10201801402XA (es)
SI (1) SI3008039T1 (es)
SM (1) SMT202100013T1 (es)
TN (1) TN2015000521A1 (es)
TW (3) TWI698428B (es)
UA (2) UA129695C2 (es)
UY (2) UY35605A (es)
WO (1) WO2014200937A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX393610B (es) 2013-11-11 2025-03-24 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
IL319432A (en) 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
MX2020012503A (es) * 2018-05-25 2021-08-11 Kartos Therapeutics Inc Métodos de tratamiento de neoplasias mieloproliferativas.
WO2020047424A1 (en) 2018-08-31 2020-03-05 Amgen, Inc. Processes for preparing a mdm2 inhibitor
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
WO2022043930A2 (en) 2020-08-27 2022-03-03 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
EP4382509A4 (en) * 2021-08-05 2025-08-27 Bio Pharm Solutions Co Ltd CRYSTALLINE FORM OF PHENYLCARBAMATE AND PROCESS FOR ITS PREPARATION
EP4398903A4 (en) * 2021-09-09 2025-07-16 Kartos Therapeutics METHODS FOR TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
GB1016828A (en) 1961-11-13 1966-01-12 Mcneilab Inc Substituted morpholines and process for preparing same
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
EP0776324B1 (en) 1994-08-19 2002-06-12 Abbott Laboratories Endothelin antagonists
NZ330818A (en) 1996-02-13 2000-05-26 Abbott Lab Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
TR200000993T2 (tr) 1997-08-04 2000-12-21 Abbott Laboratories Endotelin antagonistleri.
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
AU2002228598A1 (en) * 2000-11-20 2002-06-03 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
CN100486969C (zh) 2001-12-18 2009-05-13 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
DE602005011132D1 (de) 2004-05-18 2009-01-02 Hoffmann La Roche Neuartige cis-imidazoline
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
KR20070073791A (ko) 2004-10-18 2007-07-10 암젠 인코포레이티드 티아디아졸 화합물 및 이의 사용방법
BRPI0607863B8 (pt) 2005-02-18 2021-05-25 Mitsubishi Pharma Corp sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo
KR20100031783A (ko) 2005-03-16 2010-03-24 에프. 호프만-라 로슈 아게 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의 그의 용도
EP1871368B1 (en) 2005-04-04 2011-06-08 Eisai R&D Management Co., Ltd. Dihydropyridine compounds for neurodegenerative diseases and dementia
MX2007015511A (es) 2005-06-07 2008-03-06 Univ Ramot Sales novedosas de farmacos sicotropicos conjugados y procesos para prepararlas.
US7893268B2 (en) 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
KR20100129331A (ko) 2005-12-01 2010-12-08 에프. 호프만-라 로슈 아게 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간 상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린 유도체
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
AU2007269836A1 (en) 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
US20100092427A1 (en) 2006-07-19 2010-04-15 The University Of Georgia Research Foundation Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
WO2008021339A2 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as pr modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
CA2680853C (en) 2007-03-23 2012-07-17 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
MX2009009913A (es) 2007-03-23 2009-10-16 Amgen Inc Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
US8193199B2 (en) 2007-03-23 2012-06-05 Amgen Inc. Heterocyclic compounds and their uses
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
AU2008273891B2 (en) 2007-07-09 2012-01-12 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2694136C (en) 2007-08-02 2013-09-17 Amgen Inc. Pi3 kinase modulators and methods of use
KR101203020B1 (ko) 2007-10-09 2012-11-20 에프. 호프만-라 로슈 아게 카이랄 시스-이미다졸린
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
WO2009082038A2 (en) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
JP2011514364A (ja) 2008-03-21 2011-05-06 クロリオン ファーマ，インコーポレーテッド 置換されたピロリジン及びピペリジン化合物、その誘導体、並びに疼痛を治療するための方法
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (en) 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
CA2734363C (en) 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
EP2387570A1 (en) 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
CA2752527C (en) 2009-02-18 2014-09-23 Amgen Inc. Indole/benzimidazole compounds as mtor kinase inhibitors
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP2012526836A (ja) 2009-05-13 2012-11-01 アムジエン・インコーポレーテツド Ｐｉｋｋ阻害薬としてのヘテロアリール化合物
CA2765817A1 (en) 2009-06-25 2010-12-29 Amgen Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
US20100331306A1 (en) 2009-06-25 2010-12-30 Amgen Inc. Heterocyclic compounds and their uses
JP2012531436A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
AU2010265932B2 (en) 2009-06-25 2014-11-20 Amgen Inc. Heterocyclic compounds and their uses
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
WO2011044501A2 (en) 2009-10-09 2011-04-14 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2534667A2 (en) * 2010-02-10 2012-12-19 Mochii, Inc. (d/b/a Voxa) Aberration-correcting dark-field electron microscopy
IT1399923B1 (it) 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
TW201311938A (zh) * 2011-04-28 2013-03-16 Otsuka Chemical Co Ltd 偶氮二甲醯胺之新穎製造法
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
EP2958902B1 (en) 2013-02-19 2017-11-15 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
CN105358530A (zh) 2016-02-24
LT3008039T (lt) 2021-01-25
AU2018260844B2 (en) 2020-08-13
CR20210290A (es) 2021-07-23
PH12015502705A1 (en) 2016-03-14
PT3008039T (pt) 2021-01-13
EA201592305A1 (ru) 2016-05-31
US20230301974A1 (en) 2023-09-28
IL297860A (en) 2023-01-01
AU2020267169A1 (en) 2020-12-03
CA3115609A1 (en) 2014-12-18
US20160287570A1 (en) 2016-10-06
IL266504B (en) 2021-04-29
CR20160010A (es) 2016-02-04
KR20160018576A (ko) 2016-02-17
MA38714A1 (fr) 2017-10-31
SG11201509896VA (en) 2016-01-28
BR122020003153B1 (pt) 2022-09-27
IL281807A (en) 2021-05-31
AU2014278428B2 (en) 2018-11-15
NZ714821A (en) 2020-10-30
IL281807B (en) 2022-12-01
PE20210153A1 (es) 2021-01-26
US9757367B2 (en) 2017-09-12
US20160289178A1 (en) 2016-10-06
AU2014278428A1 (en) 2015-11-26
AU2018260844A1 (en) 2018-11-22
JOP20200296A1 (ar) 2017-06-16
PH12020550916A1 (en) 2024-03-25
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
ES2851023T3 (es) 2021-09-02
MY194848A (en) 2022-12-19
CY1123661T1 (el) 2022-03-24
AU2022271425A1 (en) 2022-12-22
AU2022271425B2 (en) 2024-06-13
AU2020267169B2 (en) 2022-08-25
NZ753956A (en) 2020-12-18
US20180092898A1 (en) 2018-04-05
CA3200532A1 (en) 2014-12-18
AR096582A1 (es) 2016-01-20
TW201922705A (zh) 2019-06-16
US20140364455A1 (en) 2014-12-11
BR112015031004A2 (pt) 2020-05-12
US20200281912A1 (en) 2020-09-10
CL2019000056A1 (es) 2019-05-03
CA3201958A1 (en) 2014-12-18
IL242622B (en) 2019-06-30
US9376386B2 (en) 2016-06-28
DK3008039T3 (da) 2021-01-04
US9801867B2 (en) 2017-10-31
TN2015000521A1 (en) 2017-04-06
KR20210121270A (ko) 2021-10-07
EA201891642A1 (ru) 2019-08-30
JP2021130685A (ja) 2021-09-09
PL3008039T3 (pl) 2021-04-19
BR112015031004B1 (pt) 2022-09-20
JP2023089126A (ja) 2023-06-27
US20160289190A1 (en) 2016-10-06
US20220280496A1 (en) 2022-09-08
TWI698428B (zh) 2020-07-11
US9855259B2 (en) 2018-01-02
JO3768B1 (ar) 2021-01-31
IL281807B2 (en) 2023-04-01
MX379872B (es) 2025-03-11
UA121301C2 (uk) 2020-05-12
AP2015008891A0 (en) 2015-11-30
CA2914723A1 (en) 2014-12-18
JP2020147573A (ja) 2020-09-17
SG10201801402XA (en) 2018-04-27
HUE053047T2 (hu) 2021-06-28
IL266504A (en) 2019-07-31
EP3008039B1 (en) 2020-11-11
MA43288B1 (fr) 2020-10-28
US20160264526A1 (en) 2016-09-15
JP7263439B2 (ja) 2023-04-24
US20160289243A1 (en) 2016-10-06
MA53572A1 (fr) 2021-10-29
AU2024216533A1 (en) 2024-09-19
EP3008039A1 (en) 2016-04-20
UY35605A (es) 2015-01-30
EA031254B1 (ru) 2018-12-28
SI3008039T1 (sl) 2021-03-31
CL2021000566A1 (es) 2021-09-03
AR119727A2 (es) 2022-01-05
CA3115609C (en) 2023-08-08
JP6891322B2 (ja) 2021-06-18
HRP20202065T1 (hr) 2021-02-19
UY40179A (es) 2023-04-14
TWI649306B (zh) 2019-02-01
KR20230019216A (ko) 2023-02-07
CA2914723C (en) 2021-06-15
KR20240159641A (ko) 2024-11-05
CN110003092A (zh) 2019-07-12
IL242622A0 (en) 2016-02-01
CL2015003589A1 (es) 2016-06-17
JP6998655B2 (ja) 2022-02-04
WO2014200937A1 (en) 2014-12-18
MA43288A1 (fr) 2020-04-30
TWI791153B (zh) 2023-02-01
CN110627708A (zh) 2019-12-31
JP2025084856A (ja) 2025-06-03
AR132854A2 (es) 2025-08-06
TW202035370A (zh) 2020-10-01
JP2016528179A (ja) 2016-09-15
EP3805232A1 (en) 2021-04-14
UA129695C2 (uk) 2025-07-09
MX2015016856A (es) 2016-04-07
PH12015502705B1 (en) 2022-04-27
MY205257A (en) 2024-10-09
EA202091612A1 (ru) 2020-10-05
US9623018B2 (en) 2017-04-18
MX2019012007A (es) 2019-11-11
SMT202100013T1 (it) 2021-03-15

Similar Documents

Publication Publication Date Title
PE20160113A1 (es) Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
CR20140464A (es) Compuestos de heterociclilo
ECSP13012612A (es) Derivados de quinazolin-4-(3h)-ona utilizados como inhibidores de p13 cinasa
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CO7380758A2 (es) Derivados de la 2-(morfolin-4-il)-3-(1-amino-3-trifluorometil-piridin-4-il)-5-(oxazol-3-il-2-ona)-pirimidina, activos como inhibidores pi3k mtor, composiciones farmacéuticas del mismo, y sus métodos de fabricación
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
AR098592A1 (es) Formas cristalinas de 1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azulenos
UY34170A (es) Formas cristalinas de 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida
MX2019006959A (es) Procesos para la preparacion de compuestos de pirimidinilciclopentano.
IN2013MU00916A (es)
ECSP12011833A (es) Proceso para la elaboración de compuestos orgánicos
MX2015004578A (es) Compuestos de flavonoides novedosos y sus usos.
EA202190632A1 (ru) Способы получения ингибитора mdm2
UY36023A (es) “derivados cristalinos de (s)-1-((2r,3r,4s,5s)-5-alil-3-metoxi-4-(tosilmetil) tetrahidrofuran-2-il)-3-aminopropan-2-ol “.